iSERA Lifesciences submits Q4 FY26 monitoring report showing minimal utilization of its ₹8.08 crore rights issue proceeds.
Only ₹0.20 crore (2.47%) was utilized for issue expenses and general corporate purposes, with ₹5 crore parked in fixed deposits.
The company reports a delay in deploying unutilized ₹7.41 crore, extending the timeline for full utilization to September 30, 2026.
Monitoring agency Infomerics confirms no deviations from the offer document but notes a post-quarter board resolution approving the delay.